The objective of this study was to determine the correlation between cytotoxic T lymphocyte-associated protein-4 (CTLA-4) expression in peripheral blood and insulin-like growth factor-1 (IGF-1) serum level as biomarkers for predicting trastuzumab treatment efficacy in HER-2 positive breast cancer. Here, ERBB2 is linked to breast carcinoma.